Bildkälla: Stockfoto

Oncopeptides: First Licensing Deal - Redeye

Redeye comments on Oncopeptides’ licensing deal for Pepaxti in South Korea.

Redeye comments on Oncopeptides’ licensing deal for Pepaxti in South Korea.
Börsvärldens nyhetsbrev
ANNONSER